TY - JOUR
T1 - Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin
T2 - Effect on quality of life after liver transplantation
AU - Volpes, Riccardo
AU - Burra, Patrizia
AU - Germani, Giacomo
AU - Manini, Matteo Angelo
AU - Caccamo, Lucio
AU - Strignano, Paolo
AU - Rizza, Giorgia
AU - Tamè, Mariarosa
AU - Pinna, Antonio Daniele
AU - Calise, Fulvio
AU - Migliaccio, Carla
AU - Carrai, Paola
AU - De Simone, Paolo
AU - Valentini, Maria Filippa
AU - Lupo, Luigi Giovanni
AU - Cordone, Gabriella
AU - Picciotto, Francesco Paolo
AU - Nicolucci, Antonio
N1 - M1 - 99
PY - 2020/4/10
Y1 - 2020/4/10
N2 - Background: Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or IM HBIG to the SC formulation. Methods: This multicentre, observational study involved adults who had undergone LT at least 1 year prior to study entry. Quality of life was evaluated using the ITaLi-Q questionnaire, assessing the impact of HBIG therapy on daily activities and patient satisfaction, and the SF-36 Health Survey. Patients completed the questionnaires prior to switching from IV or IM HBIG to SC HBIG and 6 months later. Results: Eighty-six patients were enrolled; before the switch, 68.6% were receiving IM HBIG and 31.4% IV HBIG. After 6 months, significant improvements in 7 of the 8 ITaLi-Q domains were found, particularly side effects, need for support to adhere to the therapy and satisfaction with the HBIG therapy. Significant improvements in several SF-36 domains were documented, including physical functioning, physical and emotional role limitations, pain, social functioning, physical and mental summary scores. Conclusions: The SC route of administration reduces side effects and their interference with daily life, ameliorates negative feelings, and increases patient autonomy.
AB - Background: Hepatitis B immunoglobulin (HBIG) therapy is available in intravenous (IV) or intra-muscular (IM) formulations. Recently, a subcutaneous (SC) formulation was introduced. This study evaluated changes in quality of life when liver transplant (LT) recipients were switched from IV or IM HBIG to the SC formulation. Methods: This multicentre, observational study involved adults who had undergone LT at least 1 year prior to study entry. Quality of life was evaluated using the ITaLi-Q questionnaire, assessing the impact of HBIG therapy on daily activities and patient satisfaction, and the SF-36 Health Survey. Patients completed the questionnaires prior to switching from IV or IM HBIG to SC HBIG and 6 months later. Results: Eighty-six patients were enrolled; before the switch, 68.6% were receiving IM HBIG and 31.4% IV HBIG. After 6 months, significant improvements in 7 of the 8 ITaLi-Q domains were found, particularly side effects, need for support to adhere to the therapy and satisfaction with the HBIG therapy. Significant improvements in several SF-36 domains were documented, including physical functioning, physical and emotional role limitations, pain, social functioning, physical and mental summary scores. Conclusions: The SC route of administration reduces side effects and their interference with daily life, ameliorates negative feelings, and increases patient autonomy.
KW - Acceptability of treatment
KW - Patient autonomy
KW - Questionnaire
KW - Satisfaction
KW - Side effects
U2 - 10.1186/s12955-020-01349-5
DO - 10.1186/s12955-020-01349-5
M3 - Article
VL - 18
JO - Health and Quality of Life Outcomes
JF - Health and Quality of Life Outcomes
SN - 1477-7525
IS - 1
ER -